IL253464B - Universal killer t-cell - Google Patents

Universal killer t-cell

Info

Publication number
IL253464B
IL253464B IL253464A IL25346417A IL253464B IL 253464 B IL253464 B IL 253464B IL 253464 A IL253464 A IL 253464A IL 25346417 A IL25346417 A IL 25346417A IL 253464 B IL253464 B IL 253464B
Authority
IL
Israel
Prior art keywords
killer
universal
cell
universal killer
Prior art date
Application number
IL253464A
Other languages
English (en)
Hebrew (he)
Other versions
IL253464A0 (en
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Publication of IL253464A0 publication Critical patent/IL253464A0/en
Publication of IL253464B publication Critical patent/IL253464B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL253464A 2015-01-23 2017-07-13 Universal killer t-cell IL253464B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (2)

Publication Number Publication Date
IL253464A0 IL253464A0 (en) 2017-09-28
IL253464B true IL253464B (en) 2022-04-01

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
IL253464A IL253464B (en) 2015-01-23 2017-07-13 Universal killer t-cell

Country Status (17)

Country Link
US (2) US11155786B2 (enExample)
EP (3) EP4095239A1 (enExample)
JP (1) JP6899333B2 (enExample)
KR (1) KR102479118B1 (enExample)
CN (1) CN107250351A (enExample)
AU (2) AU2016208475B2 (enExample)
CA (1) CA2973924C (enExample)
DK (1) DK3247791T3 (enExample)
EA (1) EA201791381A1 (enExample)
ES (1) ES2922231T3 (enExample)
GB (1) GB201501175D0 (enExample)
IL (1) IL253464B (enExample)
MX (1) MX390756B (enExample)
PL (1) PL3247791T3 (enExample)
PT (1) PT3247791T (enExample)
SG (1) SG11201705693XA (enExample)
WO (1) WO2016116601A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3452580B1 (en) * 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
WO2018129199A1 (en) * 2017-01-04 2018-07-12 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
EP3844499A1 (en) * 2018-08-31 2021-07-07 Invectys Sa Method to assess car functionality
EP3941490A4 (en) * 2019-03-20 2023-01-04 2seventy bio, Inc. ADOPTIVE CELLULAR THERAPY
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
CN115052965A (zh) 2019-07-29 2022-09-13 麻省理工学院 用于器官发生的合成水凝胶
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
IL301543A (en) 2020-09-24 2023-05-01 Medigene Immunotherapies Gmbh Prame specific t cell receptors and uses thereof
JP2023547695A (ja) * 2020-11-03 2023-11-13 ハンチョウ キハン バイオテック カンパニー リミテッド 増強された免疫療法のためのシステムおよび方法
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
KR20220160479A (ko) * 2021-05-27 2022-12-06 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
WO2023047089A1 (en) 2021-09-21 2023-03-30 Oslo Universitetssykehus Hf Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023078287A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
WO2024261045A1 (en) 2023-06-20 2024-12-26 Zelluna Immunotherapy As Methods of enhancing or modifying nk cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
DE69834257T2 (de) 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US7786269B2 (en) 2001-12-04 2010-08-31 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
JP5525689B2 (ja) * 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
EP2817620B1 (en) * 2012-02-22 2016-06-01 Verik Bio, Inc. A system for immunotherapy targeting tumor propagation and progression
US11471486B2 (en) 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CN105378078B (zh) 2013-02-04 2019-03-01 罗杰威廉姆斯医疗中心 用于治疗胃肠道间质瘤(gist)的方法和组合物
JP6425301B2 (ja) * 2014-05-29 2018-11-21 国立大学法人富山大学 Tcrの細胞傷害活性誘導能を評価するためのnk細胞株、およびその作製方法
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Also Published As

Publication number Publication date
US20180010097A1 (en) 2018-01-11
AU2016208475A1 (en) 2017-08-03
US20220127574A1 (en) 2022-04-28
SG11201705693XA (en) 2017-08-30
EP4681735A2 (en) 2026-01-21
PL3247791T3 (pl) 2022-09-05
KR102479118B1 (ko) 2022-12-16
JP2018512047A (ja) 2018-05-10
CA2973924C (en) 2024-06-04
JP6899333B2 (ja) 2021-07-07
EP4681735A3 (en) 2026-03-25
EP3247791A1 (en) 2017-11-29
IL253464A0 (en) 2017-09-28
EP4095239A1 (en) 2022-11-30
AU2016208475B2 (en) 2021-10-14
MX390756B (es) 2025-03-04
CA2973924A1 (en) 2016-07-28
NZ733855A (en) 2023-10-27
EA201791381A1 (ru) 2018-02-28
KR20170121178A (ko) 2017-11-01
MX2017009459A (es) 2018-04-11
AU2022200126A1 (en) 2022-02-10
BR112017015631A2 (pt) 2018-03-13
PT3247791T (pt) 2022-07-20
ES2922231T3 (es) 2022-09-12
US11155786B2 (en) 2021-10-26
GB201501175D0 (en) 2015-03-11
EP3247791B1 (en) 2022-05-04
DK3247791T3 (da) 2022-07-11
WO2016116601A1 (en) 2016-07-28
CN107250351A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
IL253464A0 (en) Universal killer t-cell
EP3858365C0 (en) T CAR CELLS OPTIMIZED WITH GOLD
EP3374114A4 (en) WORKBENCH
PT3237442T (pt) Célula
PL3118311T3 (pl) Antysensowny kwas nukleinowy
HUE053101T2 (hu) Javított T-sejt-készítmények
DK3218519T3 (da) Multipass-sekvensering
DK4032440T3 (da) Låganordning
DK3277719T3 (da) Polypeptider
PL3151327T3 (pl) Roztwór elektrolitu
EP3316375A4 (en) Redox flow cell
DK3341303T3 (da) Blisterpakning
EP3037812C0 (en) ENZYME ELECTRODE
PT3353336T (pt) Elétrodo
DK3184642T3 (da) Gærcelle
DK3270930T3 (da) Præeklampsi
DK3766582T3 (da) Cellekultur
DK3274482T3 (da) Stenborsknop
DE112015006486A5 (de) Inkubationsrinne
DE102015206660A8 (de) Plattenaufteilanlage
DE112015005898A5 (de) Gurtschlossbringer
DK3390621T3 (da) Forbedret fermentering
DE112016005599A5 (de) Strahlungsgrill
DE102015000551A8 (de) Rotationszerstäuberturbine
DE112016001124A5 (de) Spannschutz